These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37823328)

  • 41. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
    Singer S; Dean R; Zhao Q; Sharma N; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S; Andritsos L; Vasu S; Jaglowski S; William BM; Bolwell B; Pohlman B; Kalaycio M; Jagadeesh D; Hill B; Sobecks R; Devine SM; Majhail NS; Efebera YA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1107-1115. PubMed ID: 30716453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C
    Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 45. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Dreger P; Sureda A; Hermine O; Montoto S
    Bone Marrow Transplant; 2018 Dec; 53(12):1553-1559. PubMed ID: 29884850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
    Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
    Hahn L; Lim H; Dusyk T; Sabry W; Elemary M; Stakiw J; Danyluk P; Bosch M
    Sci Rep; 2021 Jul; 11(1):14071. PubMed ID: 34234243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
    Lachance S; Bourguignon A; Boisjoly JA; Bouchard P; Ahmad I; Bambace N; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Veilleux O; Zehr J; Chagnon M; Roy J
    Transplant Cell Ther; 2023 Jan; 29(1):34.e1-34.e7. PubMed ID: 36243319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
    Zaucha R; Gooley T; Holmberg L; Gopal AK; Press O; Maloney D; Bensinger WI
    Leuk Lymphoma; 2008 Oct; 49(10):1899-906. PubMed ID: 18949614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
    Puig N; de la Rubia J; Remigia MJ; Jarque I; Martín G; Cupelli L; Sanz GF; Lorenzo I; Sanz J; Martínez JA; Jiménez C; Sanz MA
    Leuk Lymphoma; 2006 Aug; 47(8):1488-94. PubMed ID: 16966258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
    Pielichowski W; Barzal J; Gawronski K; Mlot B; Oborska S; Wasko-Grabowska A; Rzepecki P
    Transplant Proc; 2011 Oct; 43(8):3107-10. PubMed ID: 21996238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
    Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
    Redondo AM; Valcárcel D; González-Rodríguez AP; Suárez-Lledó M; Bello JL; Canales M; Gayoso J; Colorado M; Jarque I; Del Campo R; Arranz R; Terol MJ; Rifón JJ; Rodríguez MJ; Ramírez MJ; Castro N; Sánchez A; López-Jiménez J; Montes-Moreno S; Briones J; López A; Palomera L; López-Guillermo A; Caballero D; Martín A;
    Br J Haematol; 2019 Mar; 184(5):797-807. PubMed ID: 30548583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
    Gunes AK; Serin I; Demir I; Sarifakiogullari S; Durusoy SS; Akkurt DM; Ince I; Ozkan G; Cinli TA; Pehlivan M
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):201-207. PubMed ID: 33933474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients.
    Xiong YY; Wang J; Wang L; Chen JB; Liu L; Tang XQ; Wang X; Zhang HB
    Sci Rep; 2022 Aug; 12(1):14369. PubMed ID: 35999255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Marchesi F; Capria S; Pedata M; Terrenato I; Ballotta L; Riccardi C; Papa E; Riemma C; Trisolini S; Celentano M; Regazzo G; Ferrara F; Mengarelli A; Picardi A
    Leuk Lymphoma; 2020 Sep; 61(9):2238-2241. PubMed ID: 32419550
    [No Abstract]   [Full Text] [Related]  

  • 60. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.